Skip to content

Study · Randomized controlled trial · n = 1,198 · 2017

2 results

Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.

Umpierrez GE, O'Neal D, DiGenio A, Goldenberg R, Hernandez-Triana E, Lin J, Park CY, Renard E, Kovatchev B

Diabetes, obesity & metabolism5 May 2017Cited by 12 (Europe PMC)

PMID28256054 (opens in a new tab)DOI10.1111/dom.12930 (opens in a new tab)PepBankPUB-28256054
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes receiving basal insulin, lixisenatide significantly reduced glucose standard deviation, MAG, MAGE, HBGI, and fasting glucose AUC versus placebo.

    In plain wordsLixisenatide reduced the listed blood sugar variability measures more than placebo in patients receiving basal insulin.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGlucose variability: standard deviation, MAG, MAGE, HBGI, and fasting glucose AUC
    Study

    n = 1,198

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged.
    1 context sentence
    Summary · context
    We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes receiving basal insulin, low blood glucose index was unchanged with lixisenatide versus placebo.

    In plain wordsThe low blood sugar index did not change with lixisenatide compared with placebo in patients receiving basal insulin.

    Peptide
    Lixisenatide
    Outcome
    No significant changeLow blood glucose index
    Study

    n = 1,198

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Values for s.d., MAG level, MAGE, HBGI, and AUC-F significantly decreased with LIXI vs placebo, while LBGI values were unchanged.
    1 context sentence
    Summary · context
    We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemic variability (GV) vs placebo as add-on to basal insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.